Elsevier

American Heart Journal

Volume 124, Issue 3, September 1992, Pages 768-774
American Heart Journal

Efficacy of lipid profiles in prediction of coronary disease

https://doi.org/10.1016/0002-8703(92)90288-7Get rights and content

Abstract

National guidelines in the United States and Europe have stimulated interest in controlling blood lipid levels to prevent CHD. In this review, the effciency of lipid profiles in predicting CHD has been examined, and total cholesterol, HDL and LDL cholesterol, and triglyceride values have been compared on the basis of 12 to 14 years of surveillance in the Framingham Study. The average value of total cholesterol and LDL cholesterol in patients who had coronary disease was at or below values that are considered dangerous, which indicates the need for more specific and sensitive lipid profiles. Measurement of LDL cholesterol levels predicted CHD only marginally better than measurement of serum total cholesterol. Measurement of triglyceride levels was the weakest predictor. The total cholesterol to HDL cholesterol ratio was the most efficient predictor both in those with apparently safe and those with abnormal cholesterol values. Measurement of HDL cholesterol was the best single lipid predictor and use of this measurement avoids needlessly alarming or falsely reassuring persons at risk for CHD who have high total cholesterol values. Since the risk associated with any serum cholesterol value varies over a 10-fold range depending on coexistent cardiovascular risk factors, these lipid factors must be taken into account in judging the hazards and efficacy of treatment needed. Evidence is available that controlling elevated cholesterol by diet and administration of pharmaceutical agents can reduce the rate of coronary events, slow progression of angiographically visualized lesions, and regress xanthomata. Hence persons at high risk for CHD who have adverse lipid and cardiovascular risk profiles can be efficiently selected for and can benefit from dietary and drug therapy.

References (20)

  • PL Canner et al.

    Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin

    J Am Coll Cardiol

    (1986)
  • J McCormick et al.

    Coronary heart disease is not preventable by population interventions

    Lancet

    (1988)
  • Lowering blood cholesterol to prevent heart disease

    JAMA

    (1985)
  • The Expert Panel

    Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults

    Arch Int Med

    (1988)
  • Consensus Development Panel

    Treatment of hypertriglyceridemia

    JAMA

    (1984)
  • The Lipid Research Clinics Program

    The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease

    JAMA

    (1984)
  • MH Frick et al.

    Helsinki Heart Study Primary Prevention Trial with gemfibrozil in middle-aged men with dyslipidemia

    N Engl J Med

    (1987)
  • DH Blankenhorn et al.

    Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous by-pass grafts

    JAMA

    (1987)
  • JF Brengke et al.

    Effects of therapy with Cholestyramine on progression of coronary atherosclerosis. Results of the NHLBI Type II Coronary Intervention Study

    Circulation

    (1984)
  • G Brown et al.

    Regression of coronary artery disease as a result of apolipoprotein B

    N Engl J Med

    (1990)
There are more references available in the full text version of this article.

Cited by (0)

Supported by The National Heart, Lung and Blood Institute Grant numbers NIH-N01-HV-92922 and NIH-N01-HV-52971; The Charles A. Dana Foundation; Merck, Sharp and Dohme; Pfizer, and Imperial Chemical Industries.

View full text